Gemina Laboratories Ltd. (GLABF)
| Previous Close | 0.3700 |
| Open | 0.3700 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.3700 - 0.3700 |
| 52 Week Range | 0.2990 - 0.6957 |
| Volume | |
| Avg. Volume | 8,102 |
| Market Cap | 27.295M |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREGemina Labs Announces Addition to its IP Portfolio
VANCOUVER, BC / ACCESSWIRE /April 9, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") today announces that it has licensed a novel biosensing architecture from the University of British Columbia. This licence is the ...
- ACCESSWIRE
Gemina Laboratories Sign First Strategic License Agreement
VANCOUVER, BC / ACCESSWIRE / April 2, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the signing of a license agreement with a significant global diagnostics company. The license agreement is ...
- ACCESSWIRE
Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships
VANCOUVER, BC / ACCESSWIRE / March 21, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide a strategic update and outlook for 2024 and beyond. The Company is beginning to see results from its 2023 ...
